Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence

·1 min read
  • Corvus Pharmaceuticals Inc (NASDAQ: CRVS) announced new data demonstrating the potential of CPI-818, an ITK inhibitor, to reduce the need for chronic human immunodeficiency virus (HIV) therapy.

  • For people living with HIV on antiretroviral therapy, HIV can be reduced to levels below detection limits, which enables the restoration and preservation of immune system function, reduces HIV-associated morbidity, and prevents HIV transmission.

  • However, in these individuals, the virus persists in a latent form in CD4 cells, which are white blood cells that are a key component of the immune system that HIV destroys.

  • Viral latency is reversed if therapy is discontinued, leading to a re-emergence of replicating HIV and destroying CD4 cells, necessitating the patients to be on life-long therapy.

  • Previous studies have shown that ITK is involved in several steps in the HIV life cycle. In this study, researchers explored the potential of ITK inhibition with CPI-818 to inhibit the latency reversal of HIV.

  • The cells were simultaneously treated with various concentrations of CPI-818. Each model showed a statistically significant and dose-dependent reduction in the reversal of viral latency, including four HIV patients.

  • In CD4 T cells, CPI-818 inhibited the proliferation of HIV-infected cells more than uninfected cells.

  • Price Action: CRVS shares are up 0.27% at $0.7520 on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence originally appeared on


© 2023 Benzinga does not provide investment advice. All rights reserved.